Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men Harry Hemingway FRCP, Alison McCallum MB/BS, Martin Shipley MSc, Kristiina.

Slides:



Advertisements
Similar presentations
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Advertisements

WHO CVD Atlas WHO Stroke Atlas The Burden of CVD in Asia: Stroke Deaths by Country,
Deepa Patel Doctor of Pharmacy Candidate, 2012 Mercer COPHS Presented on July 22, 2011.
Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
METHODS A systematic review of evidence-based literature was performed using Medline and Cochrane databases. Studies reviewed include randomized controlled.
Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Chronic kidney disease Mr James Hollinshead Public Health Analyst East Midlands Public Health Observatory (EMPHO) UK Renal Registry 2011 Annual Audit Meeting.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.
Cardiovascular Disease in Women Module I: Epidemiology.
Journal Club Hallie Lee PharmD Candidate 2013 Mercer University COPHS PHA 618 Geriatrics-Continuous Care Multivitamins in the Prevention of Cardiovascular.
Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.
European Society of Cardiology Cardiovascular diseases in women.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
BARI 2D Trial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans The Bypass Angioplasty.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Cardiovascular disease in a large cohort of depressed and/or anxious patients Results of the Netherlands Study of Depression and Anxiety N Vogelzangs 1,
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
4S: Scandinavian Simvastatin Survival Study
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Insights from the PROMISE Trial Neha J. Pagidipati, MD MPH; Kshipra Hemal; Adrian Coles, PhD; Daniel B. Mark, MD MPH; Rowena J. Dolor, MD MHS; Patricia.
以多重死因資料比較台灣美國腦中風 併發吸入性肺炎之趨勢 奇美醫學中心 張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Angela Aziz Donnelly April 5, 2016
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Journal of the American College of Cardiology
Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis  Stavros Stavrakis, MD  The American Journal.
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Health and Human Services National Heart, Lung, and Blood Institute
Clinical need for determination of vulnerable plaques
Copyright © 2007 American Medical Association. All rights reserved.
Chapter 1 Benefits and Risks Associated with Physical Activity
Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease  Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,
Section 5: Intervention and drug therapy
LRC-CPPT and MRFIT Content Points:
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Presentation transcript:

Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men Harry Hemingway FRCP, Alison McCallum MB/BS, Martin Shipley MSc, Kristiina Manderbacka PhD, Pekka Martikainen PhD, Ilmo Keskimäki MD/PhD Published in Journal of the American Medical Association 2006

www. Clinicaltrialresults.org Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men: Introduction The public health impact of stable angina, particularly among women, is poorly understood.The public health impact of stable angina, particularly among women, is poorly understood. In the US and many developed countries, coronary artery disease is the most common cause of death in women, and among women, stable angina is the most common initial symptomatic presentation.In the US and many developed countries, coronary artery disease is the most common cause of death in women, and among women, stable angina is the most common initial symptomatic presentation. However, there is an apparent paradox; angina prevalence in women is similar to that in men, in contrast with the marked male excess of myocardial infarction incidence and angiographically demonstrated coronary artery disease.However, there is an apparent paradox; angina prevalence in women is similar to that in men, in contrast with the marked male excess of myocardial infarction incidence and angiographically demonstrated coronary artery disease. The objective was to determine sex differences in chronic stable angina with respect to (1) incidence in the general population, (2) coronary mortality compared with the general population, and (3) absolute coronary event rates, by angina severity and coexisting conditions.The objective was to determine sex differences in chronic stable angina with respect to (1) incidence in the general population, (2) coronary mortality compared with the general population, and (3) absolute coronary event rates, by angina severity and coexisting conditions. The public health impact of stable angina, particularly among women, is poorly understood.The public health impact of stable angina, particularly among women, is poorly understood. In the US and many developed countries, coronary artery disease is the most common cause of death in women, and among women, stable angina is the most common initial symptomatic presentation.In the US and many developed countries, coronary artery disease is the most common cause of death in women, and among women, stable angina is the most common initial symptomatic presentation. However, there is an apparent paradox; angina prevalence in women is similar to that in men, in contrast with the marked male excess of myocardial infarction incidence and angiographically demonstrated coronary artery disease.However, there is an apparent paradox; angina prevalence in women is similar to that in men, in contrast with the marked male excess of myocardial infarction incidence and angiographically demonstrated coronary artery disease. The objective was to determine sex differences in chronic stable angina with respect to (1) incidence in the general population, (2) coronary mortality compared with the general population, and (3) absolute coronary event rates, by angina severity and coexisting conditions.The objective was to determine sex differences in chronic stable angina with respect to (1) incidence in the general population, (2) coronary mortality compared with the general population, and (3) absolute coronary event rates, by angina severity and coexisting conditions. Hemingway et al., JAMA 2006 Mar; 295(12):

www. Clinicaltrialresults.org Incidence and Prognostic Implications of Stable Angina Pectoris among Women and Men: Populations Finland has a comprehensive health care system provided to allFinland has a comprehensive health care system provided to all citizens, funded from general taxation. Using personal identity numbers, data held in national registersUsing personal identity numbers, data held in national registers in Finland were linked to create a register of patients with angina and their coexisting conditions, hospitalizations, and mortality. The denominator population used for the calculation ofThe denominator population used for the calculation of incidence risk was defined as the resident population of Finland, based on the 1990 census, who were aged 45 to 89 years in Hemingway et al., JAMA 2006 Mar; 295(12):

www. Clinicaltrialresults.org The first case definition (“nitrate angina”) was based on reimbursement for dispensed (filled) prescriptions for glyceryl trinitrate, isosorbide dinitrate, and isosorbide mononitrate (including sublingual, aerosol, transdermal, and oral preparations) during the 3- year recruitment period.*The first case definition (“nitrate angina”) was based on reimbursement for dispensed (filled) prescriptions for glyceryl trinitrate, isosorbide dinitrate, and isosorbide mononitrate (including sublingual, aerosol, transdermal, and oral preparations) during the 3- year recruitment period.* The second case definition (“test-positive angina”) was based on a special reimbursement right requiring a medical certificate by the attending physician, usually an internist or a cardiologist, which was then reviewed and approved by a specialist physician at the Social Insurance Institution.*The second case definition (“test-positive angina”) was based on a special reimbursement right requiring a medical certificate by the attending physician, usually an internist or a cardiologist, which was then reviewed and approved by a specialist physician at the Social Insurance Institution.* Such a reimbursement right is awarded only to patients with chronic angina pectoris symptoms responding to antianginal medication in the presence of unequivocal electrocardiographic changes (on exercise or at rest) or angiographic coronary artery disease.Such a reimbursement right is awarded only to patients with chronic angina pectoris symptoms responding to antianginal medication in the presence of unequivocal electrocardiographic changes (on exercise or at rest) or angiographic coronary artery disease. Incidence and Prognostic Implications of Stable Angina Pectoris in Men and Women: Angina Case Definitions *January 1, 1996, to December 31, 1998 Hemingway et al., JAMA 2006 Mar; 295(12):

www. Clinicaltrialresults.org Incidence and Prognostic Implications of Stable Angina Pectoris in Men and Women: Results The age-standardized annual incidence of nitrate angina was higher in women than in men, but for test-positive angina the incidence was lower in women.The age-standardized annual incidence of nitrate angina was higher in women than in men, but for test-positive angina the incidence was lower in women. Among all cases combined, total incidence risks were similar in women (1.89 per 100) and men (2.03 per 100), with a sex ratio of 1.07 (95% CI, ).Among all cases combined, total incidence risks were similar in women (1.89 per 100) and men (2.03 per 100), with a sex ratio of 1.07 (95% CI, ). * Annual risk per 100 population, using estimated total population of Finland in Because the case definitions of angina are mutually exclusive, the same population denominator was used for each. Hemingway et al., JAMA 2006 Mar; 295(12): Age- and Sex- Specific Annual Incidence Risk* of Nitrate Angina and Test-Positive Angina and Sex Ratios Among Incident Cases

www. Clinicaltrialresults.org In every age group, nitrate angina in women was associated with increased coronary SMRs similar in magnitude to those observed in men. In every age group, nitrate angina in women was associated with increased coronary SMRs similar in magnitude to those observed in men. Hemingway et al., JAMA 2006 Mar; 295(12): Incidence and Prognostic Implications of Stable Angina Pectoris in Men and Women: Results Prognosis of Nitrate and Test-Positive Angina: Standardized Mortality Ratios (SMRs) for Coronary Heart Disease, by Sex, Within Age Groups

www. Clinicaltrialresults.org Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men: Results Baseline Patient Characteristics According to Sex and Type of Angina: Women with angina were older than men and, in age-adjusted analyses, were slightly more likely to be using short-acting nitrates and lower defined daily doses.Women with angina were older than men and, in age-adjusted analyses, were slightly more likely to be using short-acting nitrates and lower defined daily doses. Test-positive angina patients were prescribed more nitrates than those with nitrate angina, but there was little difference between sexes in amount used; 14.7% of women and 17.2% of men were taking no nitrates (but may have been taking other antianginal medication).Test-positive angina patients were prescribed more nitrates than those with nitrate angina, but there was little difference between sexes in amount used; 14.7% of women and 17.2% of men were taking no nitrates (but may have been taking other antianginal medication). Noncardiovascular coexisting conditions were more common among women and, in both sexes, were more common in nitrate angina cases than in test-positive cases.Noncardiovascular coexisting conditions were more common among women and, in both sexes, were more common in nitrate angina cases than in test-positive cases. Among patients with diabetes test-positive angina, age-standardized event rates were 9.9 per 100 person-years in women vs. 9.3 in men (p=.69); in fully adjusted models, the male to female sex ratio for coronary events was 1.07 (95% CI, ).Among patients with diabetes test-positive angina, age-standardized event rates were 9.9 per 100 person-years in women vs. 9.3 in men (p=.69); in fully adjusted models, the male to female sex ratio for coronary events was 1.07 (95% CI, ). Hemingway et al., JAMA 2006 Mar; 295(12):

www. Clinicaltrialresults.org Among nitrate angina cases in women and men, the amount of nitrates used showed a very strong, graded relationship with coronary event rates after adjustment for demographic factors, cardiovascular and noncardiovascular conditions, and receipt of coronary revascularization.Among nitrate angina cases in women and men, the amount of nitrates used showed a very strong, graded relationship with coronary event rates after adjustment for demographic factors, cardiovascular and noncardiovascular conditions, and receipt of coronary revascularization. Hemingway et al., JAMA 2006 Mar; 295(12): Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men: Results Sex Differences in Prognostic Impact of the Severity of Angina and Coexisting Conditions on All-Cause Mortality and Fatal CHD and Nonfatal MI Among Angina Cases

www. Clinicaltrialresults.org Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men: Summary Hemingway et al., JAMA 2006 Mar; 295(12): Women had a lower incidence than men of test-positive cases of angina, consistent with previous US studies that, although not based on primary care, report underuse of investigation in women with chest pain.Women had a lower incidence than men of test-positive cases of angina, consistent with previous US studies that, although not based on primary care, report underuse of investigation in women with chest pain. This may relate to sex differences in symptom description or physician perception of risk.This may relate to sex differences in symptom description or physician perception of risk. Absolute rates of coronary events in women were high when compared with thresholds for initiating secondary prevention treatment.Absolute rates of coronary events in women were high when compared with thresholds for initiating secondary prevention treatment. Estimated 10-year risks of fatal and nonfatal myocardial infarction exceeded 10% (“moderately high”) for women with nitrate angina, even among those without cardiovascular or noncardiovascular comorbidity; absolute risks were considerably higher for women with test-positive angina.Estimated 10-year risks of fatal and nonfatal myocardial infarction exceeded 10% (“moderately high”) for women with nitrate angina, even among those without cardiovascular or noncardiovascular comorbidity; absolute risks were considerably higher for women with test-positive angina. When compared with men, women overall tended to have lower coronary event rates.When compared with men, women overall tended to have lower coronary event rates.